• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Seaport Calibre Materials Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    1/30/23 11:15:16 AM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous
    Get the next $SCMA alert in real time by email
    0001863428 false 0001863428 2023-01-30 2023-01-30 0001863428 SCMA:UnitsEachConsistingOfOneShareOfClassACommonStockDollar0.0001ParValueAndOneHalfOfOneRedeemableWarrantMember 2023-01-30 2023-01-30 0001863428 us-gaap:CommonClassAMember 2023-01-30 2023-01-30 0001863428 us-gaap:WarrantMember 2023-01-30 2023-01-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    FORM 8-K

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): January 30, 2023

     

    SEAPORT CALIBRE MATERIALS ACQUISITION CORP.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-40975   86-3426874
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (I.R.S. Employer
    Identification No.)

     

    360 Madison Avenue, 20TH Floor    
    New York, NY   10017
    (Address of principal executive offices)   (Zip Code)

     

    (212) 616-7700
    (Registrant’s telephone number, including area code)

     

    Not Applicable
    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    xSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Units, each consisting of one share of Class A Common Stock, $0.0001 par value, and one-half of one redeemable Warrant   SCMAC   The Nasdaq Stock Market LLC
    Shares of Class A common stock, included as part of the units   SCMA   The Nasdaq Stock Market LLC
    Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50   SCMAW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

    Item 1.01. Entry into a Material Definitive Agreement

     

    On January 30, 2023, Seaport Calibre Materials Acquisition Corp. (the “Company”) entered into one or more agreements (the “ Non-Redemption Agreements”) with one or more third parties holding an aggregate of 150,000 shares of common stock in exchange for them agreeing not to redeem shares of the Company’s common stock sold in its initial public offering (the “public shares”) at the January 31, 2023, special meeting of stockholders called by the Company (the “Meeting”) at which a proposal to approve an extension of time for the Company to consummate an initial business combination (the “Extension Proposal”) from February 1, 2023 to August 1, 2023 (the “Extension”) has also been submitted to the stockholders. Pursuant to the Non-Redemption Agreements, the shareholders have agreed to vote in favor of the Extension Proposal. The Non-Redemption Agreements provide for the allocation of up to 37,500 shares of Class B common stock of the Company held by the Sponsors in exchange for such investor and/or investors agreeing to hold and not redeem certain public shares at the Meeting.

     

    The Non-Redemption Agreements shall terminate on the earlier of (a) the liquidation or dissolution of the Company pursuant to its charter if the Extension is not obtained, or (b) February 1, 2023.

     

    The Non-Redemption Agreements are expected to increase the likelihood that the Extension Proposal is approved by stockholders and to increase the amount of funds that remain in the Company’s trust account following the Meeting.

     

    The foregoing summary of the Non-Redemption Agreements does not purport to be complete and is qualified in its entirety by reference to the form of Non-Redemption Agreement attached hereto as Exhibit 10.1 and incorporated herein by reference.

     

    Participants in the Solicitation

     

    The Company and its directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies from the Company’s shareholders in respect of the Meeting and the Extension and related matters. Information regarding the Company’s directors and executive officers is available in Company’s definitive proxy statement (the “Proxy Statement”) for the Meeting filed with the U.S. Securities and Exchange Commission on January 13, 2023. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests are contained in the Proxy Statement.

     

    No Offer or Solicitation

     

    This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

     

    Additional Information

     

    The Company has filed with the Securities and Exchange Commission (the “SEC”) the Proxy Statement in connection with the Meeting to consider and vote upon the Extension Proposal and other matters and, beginning on or about January 13, 2023, mailed the Proxy Statement and other relevant documents to its stockholders as of the January 5, 2023, record date for the Meeting. The Company’s stockholders and other interested persons are advised to read the Proxy Statement and any other relevant documents that have been or will be filed with the SEC in connection with the Company’s solicitation of proxies for the Meeting because these documents contain important information about the Company, the Extension Proposal and related matters. Stockholders may also obtain a free copy of the Proxy Statement, as well as other relevant documents that have been or will be filed with the SEC, without charge, at the SEC’s website located at www.sec.gov or by directing a request to: Seaport Calibre Materials Acquisition Corp., 360 Madison Avenue, 20th Floor, New York, NY 10017, (212) 616-7700.

     

     

     

     

    Forward-Looking Statements

     

    This Current Report on Form 8-K (this “Form 8-K”) includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact included in this Form 8-K are forward-looking statements. When used in this Form 8-K, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions, as they relate to us or our management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company’s filings with the SEC. All subsequent written or oral forward-looking statements attributable to the Company or persons acting on its behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the “Risk Factors” section of the Company’s Annual Report on Form 10-K, subsequent quarterly reports on Form 10-Q and initial public offering prospectus. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit
    No.
      Description
    10.1   Form of Voting and Non-Redemption Agreement
    104   Cover Page Interactive Data File (embedded within the inline XBRL document)

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: January 30, 2023 Seaport Calibre Materials ACQUISITION II CORP.
       
      By: /s/ Jim Tumulty
      Name: Jim Tumulty
      Title: Chief Executive Officer

     

     

     

    Get the next $SCMA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SCMA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SCMA
    SEC Filings

    View All

    SEC Form 15-12G filed by Seaport Calibre Materials Acquisition Corp.

    15-12G - Seaport Calibre Materials Acquisition Corp. (0001863428) (Filer)

    2/13/23 4:33:20 PM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous

    SEC Form 25-NSE filed by Seaport Calibre Materials Acquisition Corp.

    25-NSE - Seaport Calibre Materials Acquisition Corp. (0001863428) (Subject)

    2/2/23 4:15:02 PM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous

    Seaport Calibre Materials Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

    8-K - Seaport Calibre Materials Acquisition Corp. (0001863428) (Filer)

    2/1/23 9:10:38 AM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous

    $SCMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Seaport Calibre Materials Acquisition Corp. Announces It Will Redeem Its Public Shares and Will Not Consummate an Initial Business Combination

    NEW YORK, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Seaport Calibre Materials Acquisition Corp. (NASDAQ:SCMA) (the "Company") announced today that, because the Company will not consummate an initial business combination within the time period required by its Amended and Restated Certificate of Incorporation (the "Amended Charter"), the Company intends to dissolve and liquidate in accordance with the provisions of the Amended Charter, effective as of the close of business on February 1, 2023. On January 13, 2023, the Company filed with the Securities and Exchange Commission a definitive proxy statement (the "Proxy Statement") in connection with a special meeting of stockholders to consider and vot

    2/1/23 9:00:00 AM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous

    Seaport Calibre Materials Acquisition Corp. Announces Adjournment of Special Meeting of Stockholders

    NEW YORK, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Seaport Calibre Materials Acquisition Corp. (Nasdaq: SCMA) (the "Company") announced today that it has postponed the Company's Special Meeting of Stockholders to be held on January 26, 2023, until January 31, 2023, at 1:00 p.m. Eastern Time. The postponed Special Meeting will be completely virtual and stockholders will be able to attend the special meeting online, vote and submit questions by visiting https://www.cstproxy.com/seaportcalibreacquisition/2023. There will be no change in the record date as a result of this postponement, and proxies tendered prior to the postponed date will not need to be voted again. Stockholders may elect to redeem

    1/26/23 5:00:00 PM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous

    $SCMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Barclays Plc

    4 - Seaport Calibre Materials Acquisition Corp. (0001863428) (Issuer)

    8/26/22 1:50:25 PM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous

    SEC Form 3: New insider Barclays Plc claimed ownership of 1,481,560 shares

    3 - Seaport Calibre Materials Acquisition Corp. (0001863428) (Issuer)

    8/26/22 10:39:08 AM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous

    $SCMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Seaport Calibre Materials Acquisition Corp. (Amendment)

    SC 13G/A - Seaport Calibre Materials Acquisition Corp. (0001863428) (Subject)

    2/14/24 1:28:06 PM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous

    SEC Form SC 13G/A filed by Seaport Calibre Materials Acquisition Corp. (Amendment)

    SC 13G/A - Seaport Calibre Materials Acquisition Corp. (0001863428) (Subject)

    2/9/24 11:04:13 AM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous

    SEC Form SC 13G/A filed by Seaport Calibre Materials Acquisition Corp. (Amendment)

    SC 13G/A - Seaport Calibre Materials Acquisition Corp. (0001863428) (Subject)

    2/14/23 3:30:17 PM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous